Denali Therapeutics (DNLI) Long-Term Investments (2017 - 2026)
Denali Therapeutics (DNLI) posted quarterly Long-Term Investments of $63.8 million for Q1 2026, down 72.95% year-over-year from $235.8 million in Q1 2025, and down 35.13% quarter-over-quarter from $98.3 million in Q4 2025.
Denali Therapeutics (DNLI) Long-Term Investments (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Long-Term Investments for 10 consecutive years, with $63.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Long-Term Investments fell 72.95% year-over-year to $63.8 million; the TTM figure through Mar 2026 stood at $63.8 million (down 72.95% YoY), while the FY2025 annual figure was $98.3 million, down 72.64% from the prior year.
- Long-Term Investments slipped to $63.8 million in Q1 2026 per DNLI's latest filing, from $98.3 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $490.7 million in Q1 2024 and bottomed at $7.9 million in Q3 2023.
- Historically, Long-Term Investments has averaged $216.7 million across 5 years, with a median of $167.1 million in 2025.
- Annual changes were most pronounced in 2024 — Long-Term Investments jumped 5535.21% — and 2025, when it plunged 94.45%.
- Denali Therapeutics' Long-Term Investments stood at $94.2 million in 2022, then sank by 91.61% to $7.9 million in 2023, then jumped by 4446.15% to $359.4 million in 2024, then slumped by 72.64% to $98.3 million in 2025, then tumbled by 35.13% to $63.8 million in 2026.
- Business Quant data shows DNLI's Long-Term Investments at $63.8 million in Q1 2026, $98.3 million in Q4 2025, and $24.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | 229.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 229.53 Mn |
| Mar 31, 2026 | 63.79 Mn |
| Dec 31, 2025 | 98.32 Mn |
| Sep 30, 2025 | 24.70 Mn |
| Jun 30, 2025 | 78.46 Mn |
| Mar 31, 2025 | 235.84 Mn |
| Dec 31, 2024 | 359.37 Mn |
| Sep 30, 2024 | 445.46 Mn |
| Jun 30, 2024 | 450.99 Mn |
| Mar 31, 2024 | 490.72 Mn |
| Sep 30, 2023 | 7.91 Mn |
| Jun 30, 2022 | 94.22 Mn |
| Mar 31, 2022 | 250.27 Mn |
| Dec 31, 2021 | 425.45 Mn |
| Sep 30, 2021 | 319.47 Mn |
| Jun 30, 2021 | 92.52 Mn |
| Mar 31, 2021 | 38.89 Mn |
| Dec 31, 2020 | 32.70 Mn |
| Sep 30, 2020 | 20.34 Mn |
| Jun 30, 2020 | 7.23 Mn |